SCHEMBL20537007

SCHEMBL20537007

C=CCOc1cccc2cccc(O)c12

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 4/20 0.49
TSHR P16473 1/20 0.49
MAPK1 P28482 1/20 0.49
HSD17B10 Q99714 1/20 0.49
LIG1 P18858 1/20 0.43
TXNRD1 Q16881 1/20 0.41
TXNRD3 Q86VQ6 1/20 0.41
TXNRD2 Q9NNW7 1/20 0.41
CYP3A4 P08684 1/20 0.41
CYP2A6 P11509 1/20 0.41
MAPT P10636 3/20 0.40
LMNA P02545 2/20 0.40
JAK2 O60674 1/20 0.40
GAA P10253 1/20 0.40
ADRA2A P08913 1/20 0.40
ADRA2B P18089 1/20 0.40
ADRA2C P18825 1/20 0.40
SETDB1 Q15047 1/20 0.39
SLC22A1 O15245 1/20 0.38
CYP1A2 P05177 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3822715 0.87 HPGD (0.51) HPGDTSHRMAPK1HSD17B10LIG1
SCHEMBL978930 0.82 HPGD (0.50) HPGDTSHRMAPK1HSD17B10LIG1
1-Hydroxy-2-Allyloxybenzene SCHEMBL1562951 0.81 GAA (0.59) HPGDTSHRMAPK1HSD17B10LIG1
SCHEMBL20554231 0.79 TSHR (0.45) HPGDTSHRMAPK1HSD17B10LIG1
SCHEMBL7072808 0.79 HPGD (0.47) HPGDTSHRMAPK1HSD17B10LIG1
SCHEMBL15814879 0.77 CYP3A4 (0.49) HPGDTSHRMAPK1HSD17B10LIG1
SCHEMBL4865834 0.77 HPGD (0.46) HPGDTSHRMAPK1HSD17B10LIG1
SCHEMBL11883080 0.77 MEN1 (0.48) HPGDMAPK1HSD17B10CYP3A4MAPT
SCHEMBL15946499 0.77 ALDH1A1 (0.41) HPGDTSHRMAPK1HSD17B10CYP3A4
SCHEMBL4192226 0.76 HPGD (0.45) HPGDTSHRMAPK1HSD17B10LIG1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-108368069-B Oxazine compound, composition and cured product DIC株式会社 2022-10-14 CN disclosed
CN-108473642-B Oxazine compound, composition and cured product DIC株式会社 2021-05-07 CN disclosed
US-10913725-B2 Oxazine compound, composition and cured product DIC CORPORATION (JP) 2021-02-09 US disclosed
US-10399312-B2 Oxazine compound, composition and cured product DIC CORPORATION (JP) 2019-09-03 US disclosed
US-20180362479-A1 OXAZINE COMPOUND, COMPOSITION AND CURED PRODUCT DIC CORPORATION (JP) 2018-12-20 US disclosed
US-20180333941-A1 OXAZINE COMPOUND, COMPOSITION AND CURED PRODUCT DIC CORPORATION (JP) 2018-11-22 US disclosed
EP-3401311-A1 OXAZINE COMPOUND, COMPOSITION AND CURED PRODUCT DIC Corporation (JP) 2018-11-14 EP disclosed
EP-3392281-A1 OXAZINE COMPOUND, COMPOSITION AND CURED PRODUCT DIC Corporation (JP) 2018-10-24 EP disclosed
CN-108473642-A Oxazine compound, composition and cured product DIC株式会社 2018-08-31 CN disclosed
CN-108368069-A Oxazine compound, composition and cured product DIC株式会社 2018-08-03 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180333941-A1 OXAZINE COMPOUND, COMPOSITION AND CURED PRODUCT KDM5A, PSMB5, CUL5 HPGD 1322/4885TSHR 4872/4885MAPK1 3958/4885
US-10913725-B2 Oxazine compound, composition and cured product PSMB5, KDM5A, CUL5 HPGD 1165/4885TSHR 4868/4885MAPK1 3792/4885
US-20180362479-A1 OXAZINE COMPOUND, COMPOSITION AND CURED PRODUCT PSMB5, KDM5A, CUL5 HPGD 1165/4885TSHR 4868/4885MAPK1 3792/4885
US-10399312-B2 Oxazine compound, composition and cured product KDM5A, PSMB5, CUL5 HPGD 1322/4885TSHR 4872/4885MAPK1 3958/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.